App-Quantinova.ai

USE OF HYDROXYCHLOROQUINE AND SYSTEMIC SCLEROSIS: RESULTS FROM A PROSPECTIVE OBSERVATIONAL STUDY ON THE EUSTAR COHORT

S. Bellando Randone - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

Hydroxychloroquine

COMBINED PROTEASOME AND AUTOPHAGY INHIBITION IN RELAPSED/REFRACTORY MULTIPLE MYELOMA – A PHASE I TRIAL OF HYDROXYCHLOROQUINE, CARFILZOMIB AND DEXAMETHASONE

Tobias S. Slrdahl - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Hydroxychloroquine

IMPACT OF THE ABCB1 DRUG RESISTANCE GENE ON COMPLICATIONS ASSOCIATED WITH COVID-19

Christian Ramos - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Hypertension

Hydroxychloroquine

HEMATOLOGIC PARAMETERS IN ASYMPTOMATIC PATIENTS WITH ACTIVE COVID-19 INFECTION.

Mounir Ababou - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

Hydroxychloroquine

Hydroxychloroquine as an adjunct treatment for patients with triple positive thrombotic antiphospholipid syndrome- a single centre experience

C. Crossette-Thambiah - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Antiphospholipid syndrome

Hydroxychloroquine

Platelets And Neutrophils Co-Drive Procoagulant Potential in Antiphospholipid Syndrome During Pregnancy

E. Agbani - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Antiphospholipid syndrome

Hydroxychloroquine

Progressive lung disease caused by ABCA3 mutation

Tuğba Şişmanlar Eyuboglu - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Pulmonary alveolar proteinosis

Hydroxychloroquine

Lymphoid interstitial pneumonia should be suspected in children with autoimmune disease and immune deficiency

Busra Köseoğlu - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Rheumatoid arthritis

Hydroxychloroquine

Pregnancy outcomes following recurrent first-trimester miscarriage: a retrospective cohort study

L Linehan - European Society for Human Reproduction and Embryology (ESHRE) , 2022

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Hypothyroidism

Hydroxychloroquine

Are dmard therapies effective on quality of life, anxiety and depression levels in patients with rheumatoid arthritis?

G.I Kinikli - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Hydroxychloroquine

Association between concomitant use of sulfasalazine and decrease of anti-ccp antibody levels in rheumatoid arthritis patients treated with tumour necrosis factor inhibitor or abatacept

H.-H. Chen - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Hydroxychloroquine

Belief about medicine questionnaire predicts therapeutic adhesion to hydroxychloroquine during systemic lupus erythematosus

Y. Rozban - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

Cost-effectiveness analysis for the treatment of early rheumatoid arthritis with biologic disease-modifying antirheumatic drugs (DMARDS compared to standard of care in singapore

J. N. Chua - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Hydroxychloroquine

Do certain dmards increase risk of new-onset type 2 diabetes? evaluation of patients’ baseline characteristics

E. Alemao - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Type 2 diabetes mellitus

Hydroxychloroquine

Effect of metformin on the absolute number of cd4+ t cell subsets in patients with primary sjogren’s syndrome

X. Sun - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Sjogren's syndrome

Hydroxychloroquine

Evaluation of tissue specific autoantibodies in fibromyalgia patients with sicca and/or xerostomia

E. Applbaum - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Fibromyalgia

Hydroxychloroquine

Extracellular vesicle-mediated delivery of ebv small rna (EBER1 activates lupus nephritis related antiviral immunity in tubular epithelial cells via tlr3

R. Baglio - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Focal segmental glomerulosclerosis

Hydroxychloroquine

A phase 2 study of safety and efficacy of lenabasum (JBT-101, a cannabinoid receptor type 2 agonist, in refractory skin-predominant dermatomyositis

V.P. Werth - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Juvenile dermatomyositis

Hydroxychloroquine

A practical simple dose escalation regimen for mild hydroxychloroquine-induced hypersensitivity reaction

E. Takamasu - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

Hydroxychloroquine

Adherence to rcophth guidelines in monitoring of hydroxychloroquine by rheumatologists at lnwh cmh

Q Adamjee - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

Hydroxychloroquine

Filters

1151 Abstracts